August 2025

Vetion Tirzepatide Injection Achieves WHO Prequalification Milestone, Accelerating Global Access to Affordable GLP-1 Therapy

Leave a Comment / Product Updates /

August 27, 2025 – Vetion Pharmaceuticals, a pioneer in metabolic disease therapeutics, announces that its Tirzepatide injection has entered the World Health Organization (WHO) International Quality Prequalification (PQ) review phase. This critical step positions Vetion to supply high-quality, cost-effective Tirzepatide to low- and middle-income countries (LMICs), addressing urgent global needs in diabetes and obesity management. […]

Vetion Tirzepatide Injection Achieves WHO Prequalification Milestone, Accelerating Global Access to Affordable GLP-1 Therapy Read More »

2023 International Diabetes Congress: GLP-1 Drugs Become Research Focus

Leave a Comment / Industry News /

At the recently concluded 2023 International Diabetes Congress, GLP-1 receptor agonists (GLP-1 RAs) emerged as the central theme, with experts and scholars highlighting their transformative role in diabetes management, obesity treatment, and beyond-metabolic health benefits. As a leading GLP-1 drug wholesaler, Vetion synthesizes key insights from the congress to showcase why these therapies are reshaping

2023 International Diabetes Congress: GLP-1 Drugs Become Research Focus Read More »

Correct Usage and Precautions for Semaglutide Injection

Leave a Comment / Other channels /

Semaglutide injection is a GLP-1 receptor agonist widely used for type 2 diabetes management and chronic weight loss. As a wholesale supplier of GLP-1 drugs, Vetion provides this comprehensive guide to ensure safe administration, optimal dosing, and proper storage for healthcare providers and patients. 1. Correct Usage of Semaglutide Injection Step-by-Step Administration Guide Preparation ●

Correct Usage and Precautions for Semaglutide Injection Read More »

Vetion Semaglutide Oral Tablets Obtain Thai FDA Marketing Authorization

Leave a Comment / Product Updates /

Vetion® Semaglutide Oral Tablets Obtain Thai FDA Marketing Authorization, Expanding Global Access to Affordable GLP-1 Therapy August 26, 2025 – Vetion Pharmaceuticals, a leader in metabolic disease therapeutics, is proud to announce that its semaglutide oral tablets have received marketing authorization from the Thai Food and Drug Administration (Thai FDA). This milestone enables Vetion to

Vetion Semaglutide Oral Tablets Obtain Thai FDA Marketing Authorization Read More »

2023 GLP-1 Drug Market Report: Global Scale to Exceed $20 Billion

Leave a Comment / Industry News /

August 26, 2023 – The latest industry research report shows that the GLP-1 drug market is growing at an average annual rate of 35%, and the global GLP-1 receptor agonist (GLP-1 RA) market has emerged as one of the most dynamic sectors in pharmaceuticals, with **2023 sales reaching 20 billion. Driven by groundbreaking efficacy in

2023 GLP-1 Drug Market Report: Global Scale to Exceed $20 Billion Read More »

Vetion’s New Factory Officially Put into Production, Annual Capacity Increased to 50 Million Units

Leave a Comment / Company News /

November 15, 2023 – Vetion, a leading innovator in metabolic therapeutics, has officially launched its state-of-the-art GLP-1 drug production base in Laos, significantly boosting its annual manufacturing capacity to 50 million units. This strategic expansion enhances Vetion’s ability to meet the surging global demand for GLP-1 receptor agonists, widely used in type 2 diabetes and

Vetion’s New Factory Officially Put into Production, Annual Capacity Increased to 50 Million Units Read More »